| Document |
Document Title |
|
JP2011502167A |
The present invention provides compounds having the general structure A, or a pharmaceutically acceptable derivatives thereof: wherein R is an alkyl group, and R1 comprises at least one moiety selected from a group consisting of an alkyl...
|
|
JP4615478B2 |
The present invention is a method of preventing or reducing atherosclerosis or restenosis, and a pharmaceutical preparation used therefore. In particular, it is a method of preventing or reducing atherosclerosis or restenosis after arter...
|
|
JP4611287B2 |
Provided is a production process by which a novel alicyclic oxetane compound which has an oxetane ring, has excellent light transmission in the near ultraviolet region, and is useful as a cationically polymerizable monomer can be easily ...
|
|
JP4610452B2 |
|
|
JP2011500658A |
Compounds of formula (I): or pharmaceutically acceptable salts thereof, are agonists of GPR119 and are useful for the treatment of diabetes and as peripheral regulators of satiety, e.g. for the treatment of obesity and metabolic syndrome.
|
|
JP4604719B2 |
There are provided various optical materials which contain a curable fluorine-containing polymer (I) having a number average molecular weight of from 500 to 1,000,000 and represented by the formula (1): &lparstr& M &rparstr& &lparstr& A ...
|
|
JP4604531B2 |
|
|
JP4600054B2 |
|
|
JP4597115B2 |
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol...
|
|
JP2010270145A |
To provide a novel 13-ketobaccatin III, a taxane derivative and a method for production thereof.The method for production of the taxane derivative includes functionalizing the 14-position of a 13-ketobaccatin derivative, and further conv...
|
|
JP2010265274A |
To provide a new method for producing N-debenzoylpaclitaxel which is a precursor of paclitaxel having antitumor activity. The method includes condensation of a carboxylic acid expressed by formula (II) (in the formula, R1 is aryl or hete...
|
|
JP4586520B2 |
Provided are a liquid-crystal compound and a liquid-crystal composition containing the compound, of which the advantages are that they show nematic hybrid orientation on a rubbed TAC substrate, they are polymerizable in open air and they...
|
|
JP2010535201A |
The present invention relates to a method of treating cancer by pretreatment with anti-mitotic agents followed by at least one aurora kinase inhibitor. Extensive illustrations are provided for the antimitotic agents and aurora kinase inh...
|
|
JP2010535171A |
The present invention relates to compounds of formula wherein Ar, R1, R2, R3, R4, R5, n, o, and p are as defined herein or to pharmaceutically suitable acid addition salts, optically pure enantiomers, racemates or diastereomeric mixtures...
|
|
JP2010254696A |
To provide a composition of a Transferrin-drug conjugate for use in cancer treatment, a method of forming a molecular conjugate used for cancer treatment such as a transferrin-drug conjugate, and an intermediate used therefor.There is pr...
|
|
JP4576832B2 |
|
|
JP4576676B2 |
|
|
JP4576429B2 |
Novel conjugates of taxol and novel immunogens derived from the 9 and 7 positions of taxol and monoclonal antibodies generated by these taxol linked immunogens are useful in immunoassays for the quantification and monitoring of taxol in ...
|
|
JP4575975B2 |
A purified antibody is disclosed which specifically binds a TRAIL receptor DR5, wherein said antibody: a) has apoptosis-inducing activity in the absence of secondary crosslinking in target cells expressing DR5 in vitro, wherein the apopt...
|
|
JP4569189B2 |
|
|
JP4563994B2 |
Disclosed is a process for isolating and purifying paclitaxel from a natural resource of taxanes, comprising the steps of (a) washing a raw material comprising paclitaxel with water in order to remove soluble impurities from the raw mate...
|
|
JP2010532769A |
The present invention relates to compounds of formula I, The compounds of formula I are valuable pharmacologically active compounds. They exhibit a strong anti-thrombotic effect and are suitable, for example, for the therapy and prophyla...
|
|
JP4561120B2 |
In the production of 2,2,3,3-tetrafluorooxetane by reaction of tetrafluoroethylene with a compound of formaldehyde generation source in anhydrous hydrogen fluoride, the reaction is carried out in the presence of polyfluoroalkylcarboxylic...
|
|
JP4561218B2 |
|
|
JP4563632B2 |
A process for the extraction and purification of Paclitaxel from a natural source of taxanes. This process comprises the following steps: a) extracting with an organic solvent, a raw material comprising Paclitaxel from said natural sourc...
|
|
JP4557500B2 |
The present invention relates to a novel fluorine-containing cyclic compound that is derived from a norbornadiene and hexafluoroacetone and has an oxacyclopentane or oxacyclobutane structure. This compound may be represented by the follo...
|
|
JP4553373B2 |
|
|
JP4546826B2 |
Lactones are prepared by catalytic carbonylation of oxiranes using a catalyst system comprising a) at least one cobalt compound as component A and b) at least one metal compound of the formula (I) as component B, MXxRn-x (I) where M is a...
|
|
JP2010195704A |
To provide a novel oxetane derivative necessary for preparation of a crosslinkable liquid crystal film excellent in orienting properties, heat resistance and molding processability, and a crosslinkable liquid crystalline polymer obtained...
|
|
JP4531410B2 |
|
|
JP4528074B2 |
|
|
JP2006519184T5 |
|
|
JP2010159263A |
To provide a compound, conjugate and immunogen useful for determination and tracking of taxol in a biological fluid in immunoassay. There is provided a compound expressed by formula II-B or its conjugate with a carrier or an immunogenic ...
|
|
JP4507398B2 |
|
|
JP2010523647A |
The present invention provides a stable anhydrous crystalline docetaxel which has anti-tumor and anti-leukemia activity, and method for the preparation thereof.
|
|
JP4502338B2 |
A taxoid compound represented by general formula (I) where the symbols R1, R2, R3, R4, Bz, and Ac have specified meanings. Also, a method for producing the taxoid derivative from a baccatin derivative having a β-ketoester group at the 1...
|
|
JP2010150170A |
To provide a method for producing a high purity alkyl ketene dimer having a reduced amount of impurities in the absence of an organic solvent in a good yield. In the method for producing the alkyl ketene dimer by reacting a fatty acid ch...
|
|
JP4499383B2 |
|
|
JP4493755B2 |
|
|
JP2010138084A |
To provide a method for obtaining crystalline docetaxel trihydrate by suspending anhydrous crystalline docetaxel in water and subsequently filtering and drying it. Anhydrous crystalline docetaxel is suspended in 1-100 volume equivalent o...
|
|
JP4482555B2 |
This invention is directed to a method for isolating and/or purifying one or more taxanes from materials comprising taxanes. In one embodiment, the method comprises the steps of (a) treating a taxane containing material with an amino con...
|
|
JP4476536B2 |
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol...
|
|
JP4471414B2 |
|
|
JP4467976B2 |
A process for the preparation of 14beta-hydroxy-baccatin III-1,14-carbonate useful for the preparation of novel taxane derivatives with antitumor activity.
|
|
JP4469606B2 |
Alkylketene dimers are prepared by reacting acyl chlorides with tertiary amines in a molar ratio of from 1:1 to 1:1.6 at from 65 to 150° C. and with a residence time of from 1 to 30 minutes in the absence of solvents with thorough mixin...
|
|
JP4467978B2 |
The present invention relates to a method for producing a 2-hydroxypropyl-beta-cyclodextrin inclusion complex of taxol, said 2-hydroxypropyl-beta-cyclodextrin having a degree of substitution of 0.4 to about 0.9, wherein the method compri...
|
|
JP2010111695A |
To provide a novel chemical compound prepared by chemically bonding a taxane to a cell binding agent capable of targeting a selected cellular population.An effective taxane containing a linking group and a cytotoxic agent including one o...
|
|
JP2010106040A |
To provide new cytotoxic matter to induce a cell death in a selected cell population.The new cytotoxic matter includes new taxanes of 2'(3'-dephenyl-3'-(isobutenyl)-7-(methyldisulphanyl-propanoy
l)-docetaxel) or the like which have a bin...
|
|
JP4460249B2 |
This application is directed to novel fluorinated polymers and prepolymers derived from mono-substituted oxetane monomers having fluorinated alkoxymethylene side-chains and the method of making these compositions. The mono-substituted fl...
|
|
JP2010100628A |
To provide prodrugs of bioactive ingredients, using high molecular weight nonantigenic polymer.The prodrug is represented by formula (I): D-O-CO-CHR1-NHR3, wherein: D is a residue of biologically active moiety; R1 represents aryl or the ...
|
